Other languages AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-09 EDT			5-day change	1st Jan Change
2.47 ^USD	+1.23%		-2.76%	-87.95%

04-03	North American Morning Briefing : Powell Awaited -2-	DJ
04-02	JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AN2 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
AN2 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28
US Equity Markets Close Mixed Monday Ahead of Inflation Data for January	02-12
Sector Update: Health Care Stocks Mixed Late Afternoon	02-12
Sector Update: Health Care	02-12
Top Midday Decliners	02-12
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	02-12
Sector Update: Health Care	02-12
Traders Search for Cues Ahead of Busy Week for Earnings, Data, Stifling US Equity Futures Pre-Bell	02-12
AN2 Therapeutics Shares Plunge Pre-Bell After Pausing Phase 3 Enrollment in Lung Disease Drug Trial	02-12
Top Premarket Decliners	02-12
AN2 Therapeutics to pause lung disease study enrollment	02-12
AN2 Therapeutics, Inc. Announces to Voluntary Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	02-12
An2 Therapeutics Insider Sold Shares Worth $1,911,410, According to a Recent SEC Filing	01-22
AN2 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
An2 Therapeutics Insider Sold Shares Worth $1,704,513, According to a Recent SEC Filing	23-10-04
An2 Therapeutics Insider Sold Shares Worth $150,708, According to a Recent SEC Filing	23-09-29
AN2 Therapeutics Begins Phase 3 in Trial for Lung Disease Treatment	23-09-13
AN2 Therapeutics, Inc. Commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex Lung Disease	23-09-13
Insider Sell: An2 Therapeutics	23-09-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Other languages

Filters